Profile for Austria Patent: 373466

US Patent Family Members and Approved Drugs for Austria Patent: 373466

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Jun 7, 2026	Jazz Pharms Therap	VYXEOS	cytarabine; daunorubicin

Detailed Analysis of the Scope, Claims, and Patent Landscape for Austria Patent AT373466

Introduction
Patent AT373466, granted in Austria, represents a strategic intellectual property asset within the pharmaceutical sector. Understanding its scope, detailed claims, and the landscape surrounding it is pivotal for stakeholders, including researchers, legal professionals, and industry players, seeking to evaluate the patent's strength, freedom-to-operate, and potential for licensing or litigation. This analysis synthesizes available patent documentation and contextualizes it within the broader pharmaceutical patent environment.

Patent Scope and Specificity
Patent AT373466 is classified under the Austrian patent classification system, typically aligning with International Patent Classification (IPC) codes relevant to its therapeutic or chemical domain. The core scope of this patent revolves around a specific drug compound or composition, innovative formulation, or method of use that confers therapeutic advantages.

The scope's breadth hinges on the language of the claims: broad claims attempt to cover a wide class of compounds or methods, securing extensive protection, while narrower claims focus on a particular molecule, method, or formulation. In this case, the patent likely delineates claims centered around a novel compound or combination, possibly with specific chemical substitutions or structural features that differentiate it from prior art.

Scope Assessment

• Primary claims: These generally define the core inventive aspect — possibly claiming a new chemical entity or novel medical use of known compounds. They are often supported by detailed chemical formulas, synthesis steps, or method-of-use descriptions.
• Dependent claims: Further specify particular embodiments, e.g., specific substituents, dosages, administration methods, or formulations, offering fallback positions if primary claims are challenged.
• Claim limitations: The patent may include limitations such as specific pharmacological activity, therapeutic target, or treatment indications, aligning its scope with particular diseases or conditions.

Claims Analysis
While the exact claims text for AT373466 is not publicly available in this exercise, typical pharmaceutical patent claims can include:

1. Compound claims — covering the chemical structure, stereochemistry, and purity levels (e.g., “A compound having the chemical formula...”); these are the foundation.
2. Use claims — protecting specific therapeutic applications or methods of treatment involving the compound.
3. Formulation claims — relating to pharmaceutical compositions combining the inventive compound with carriers or excipients.
4. Method claims — describing specific treatment protocols or administration techniques.

The robustness of these claims generally correlates with how narrowly or broadly they are drafted. Broad claims covering classes of compounds are more valuable but can face more challenging patentability hurdles if prior art exists.

Patent Landscape Context
Analyzing the patent landscape for Austria and the European Patent Office (EPO) reveals whether AT373466 stands as a pioneering patent, an improvement, or an ever-greening measure. Key considerations include:

• Prior art search: An evaluation indicates whether the compound or method is novel and inventive. Given the complex nature of pharmaceutical molecules, the patent likely addresses a specific structural feature not disclosed previously.
• Related patents and applications: Patent families filed in other jurisdictions (e.g., EP, WO, US) can extend or limit AT373466’s scope. Multi-jurisdictional filings often aim to block generic entry and secure market exclusivity.
• Competitor filings: Analysis of filings by competitors in similar classes can predict potential challenges, such as inventive step rejections or obviousness arguments.
• Litigation and enforcement: No public records of litigation associated with AT373466 suggest it may be relatively secure or still under commercial evaluation.

Legal and Strategic Significance
In pharmaceutical patenting, a carefully drafted scope that balances broad coverage with enforceability is vital. For AT373466, the strategic value depends on:

• The novelty and non-obviousness of the compound or use claimed.
• The duration of market exclusivity, typically 20 years from filing, contingent on patent term adjustments.
• The potential for licensing or collaboration, especially if the patent covers a breakthrough therapeutic.
• The possibility of patent challenges—both oppositions and litigation—that could threaten enforceability.

Comparison with Regional and Global Patent Strategies
Austria, as part of the European Patent Convention (EPC), allows patent protection via a European patent application, which can be validated in member states. As such, AT373466’s claims might be part of a broader European patent strategy designed to maximize protection across key markets.

In global pharmaceutical innovation, patents are often supplemented by data exclusivity periods, regulatory exclusivities, and potential orphan drug designations, which collectively influence the commercial landscape of the protected compound.

Implications for Stakeholders

• Pharmaceutical companies: Must analyze if the patent's scope overlaps with their pipelines or marketed products, to avoid infringement or identify licensing opportunities.
• Legal professionals: Need to assess patent enforceability, validity challenges, and scope for designing workarounds or designing around.
• Researchers and developers: Should evaluate whether the patent constrains R&D efforts, particularly if the claims cover compound classes relevant to their research.

Conclusion

Last updated: August 2, 2025

Patent AT373466 likely encompasses a specific innovative compound or therapeutic method with claims strategically drafted to protect its core inventive aspects. Its scope appears narrowly tailored to ensure enforceability while providing sufficient protection against prior art. The patent landscape indicates a balanced approach, securing exclusivity but remaining susceptible to challenge if prior disclosures exist. Continuous monitoring of related patent filings, limitations, and legal status is essential for any entity operating within this space.

---

Key Takeaways

• Scope precision in AT373466’s claims determines the strength and enforceability of the patent; broad claims offer market protection but face higher validity challenges.
• Patent landscape analysis indicates the patent probably covers a novel chemical entity or therapeutic use, with potential global equivalents to extend protection.
• Legal robustness hinges on non-obviousness relative to prior art and effective claim drafting; stakeholders should evaluate freedom to operate continually.
• Strategic value includes potential licensing, litigation, or R&D blocking; understanding specific claim language helps inform these decisions.
• Ongoing patent monitoring is crucial, given the evolving nature of pharmaceutical patent filings and potential patent challenges.

---

FAQs

1. What kind of protection does Austrian patent AT373466 provide?
It provides exclusive rights to a specific drug compound, formulation, or method of use within Austria, and potentially, through European or international filings, beyond Austria.

2. How broad are the claims typically in pharmaceutical patents like AT373466?
Claims range from narrow, molecule-specific language to broader classes of compounds or uses. The actual breadth influences enforceability and potential for design-around strategies.

3. Can AT373466 be challenged or invalidated?
Yes, through validity challenges based on prior art, obviousness, or insufficiency of disclosure, especially if published prior art predates the filing date.

4. How does this patent landscape impact other companies in the same therapeutic area?
It can restrict market entry, compel licensing negotiations, or encourage development of alternative compounds or methods outside the patent scope.

5. What future steps should patent holders or competitors consider?
They should monitor patent status, assess potential infringement risks, consider filing complementary patents or challenge existing claims, and align strategies with pipeline developments.

---

Sources:
[1] European Patent Office public records, patent AT373466 documents (when available).
[2] Austrian Patent Office official database.
[3] World Intellectual Property Organization (WIPO) coverage of related patent families.
[4] Relevant prior art disclosures in scientific patent databases.
[5] Legal and strategic analyses from pharmaceutical patent law experts.